相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease
D. Erkan et al.
LUPUS (2018)
EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome
L. Andreoli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?
A. S. Resseguier et al.
LUPUS (2017)
The use of direct oral anticoagulants in 56 patients with antiphospholipid syndrome
Katarzyna Malec et al.
THROMBOSIS RESEARCH (2017)
The impact of body weight on rivaroxaban pharmacokinetics
Sarah J. Barsam et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2017)
The Effects of Indirect- and Direct-Acting Anticoagulants on Lupus Anticoagulant Assays A Large, Retrospective Study at a Coagulation Reference Laboratory
Jansen N. Seheult et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2017)
Recurrent venous thromboembolism and abnormal uterine bleeding with anticoagulant and hormone therapy use
Ida Martinelli et al.
BLOOD (2016)
Apixaban for the Secondary Prevention of Thrombosis Among Patients With Antiphospholipid Syndrome: Study Rationale and Design (ASTRO-APS)
Scott C. Woller et al.
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2016)
Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases
Flavio Signorelli et al.
CLINICAL RHEUMATOLOGY (2016)
Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial
V. Pengo et al.
LUPUS (2016)
An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban
Huaibin Wan et al.
BLOOD COAGULATION & FIBRINOLYSIS (2016)
Antithrombotic Therapy for VTE Disease CHEST Guideline and Expert Panel Report
Clive Kearon et al.
CHEST (2016)
Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH
H. Cohen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
The laboratory's 2015 perspective on direct oral anticoagulant testing
R. C. Gosselin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH
K. Martin et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism
D. R. J. Arachchillage et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2016)
Direct oral anticoagulants in antiphospholipid syndrome: a real life case series
J. F. Betancur et al.
LUPUS (2016)
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Stuart J. Connolly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The effect of the direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a comprehensive assessment using in vitro and ex vivo samples
Roslyn Bonar et al.
PATHOLOGY (2016)
Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting
Jan Beyer-Westendorf et al.
THROMBOSIS AND HAEMOSTASIS (2016)
Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience
D. R. J. Arachchillage et al.
THROMBOSIS RESEARCH (2016)
Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism in the presence of thrombophilia: Findings from RE-COVER®, RE-COVER II, and RE-MEDY™
Samuel Z. Goldhaber et al.
VASCULAR MEDICINE (2016)
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature
Virginie Dufrost et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
Rivaroxaban to treat thrombotic antiphospholipid syndrome
Rolf T. Urbanus
Lancet Haematology (2016)
Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial
Hannah Cohen et al.
Lancet Haematology (2016)
Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome
Nicolas Noel et al.
AUTOIMMUNITY REVIEWS (2015)
Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism
Sciascia Savino et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome
Tadeusz Goralczyk et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Assessing nonvitamin K antagonist oral anticoagulants (NOACs) in the laboratory
R. C. Gosselin et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome
D. R. J. Arachchillage et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)
How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters
Armando Tripodi et al.
THROMBOSIS RESEARCH (2015)
Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism
D. R. J. Arachchillage et al.
THROMBOSIS RESEARCH (2015)
The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases
Maksim Son et al.
THROMBOSIS RESEARCH (2015)
Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome
Maria Efthymiou et al.
THROMBOSIS RESEARCH (2015)
Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients
R. Cervera et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Warfarin Monitoring in Antiphospholipid Syndrome and Lupus Anticoagulant
Ashley Crowl et al.
ANNALS OF PHARMACOTHERAPY (2014)
Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry
Jan Beyer-Westendorf et al.
BLOOD (2014)
Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism
Clive Kearon et al.
BLOOD (2014)
Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin
M. E. Martinuzzo et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2014)
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)
Maria J. Cuadrado et al.
RHEUMATOLOGY (2014)
Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban
Richard Herrmann et al.
THROMBOSIS AND HAEMOSTASIS (2014)
Guideline on the management of bleeding in patients on antithrombotic agents
Mike Makris et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Apixaban for Extended Treatment of Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Giancarlo Agnelli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions
Helen Mani et al.
THROMBOSIS AND HAEMOSTASIS (2013)
Estimated Frequency of Antiphospholipid Antibodies in Patients With Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature
Laura Andreoli et al.
ARTHRITIS CARE & RESEARCH (2013)
Surrogate Outcomes in Clinical Trials A Cautionary Tale
Staffan Svensson et al.
JAMA INTERNAL MEDICINE (2013)
Guidelines on the investigation and management of antiphospholipid syndrome
David Keeling et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Shannon M. Bates et al.
CHEST (2012)
Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Anne Holbrook et al.
CHEST (2012)
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests
Walter-Michael Halbmayer et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2012)
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
Harry R. Buller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux
Meyer Michel Samama et al.
THROMBOSIS RESEARCH (2012)
Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study
Vittorio Pengo et al.
BLOOD (2011)
Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation
Farah Yasmine Huq et al.
CONTRACEPTION (2011)
Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time
G. M. A. Van Os et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2011)
Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies
G. Ruiz-Irastorza et al.
LUPUS (2011)
Rivaroxaban and false positive lupus anticoagulant testing
Eileen Merriman et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Thrombotic risk assessment in the antiphospholipid syndrome requires more than the quantification of lupus anticoagulants
Katrien Devreese et al.
BLOOD (2010)
Clinical course of high-risk patients diagnosed with antiphospholipid syndrome
V. Pengo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2010)
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
Rupert Bauersachs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression
Anselm Mak et al.
RHEUMATOLOGY (2010)
Update of the guidelines for lupus anticoagulant detection
V. Pengo et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2009)
Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography
Katrien Devreese et al.
THROMBOSIS AND HAEMOSTASIS (2009)
A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies
Guillermo Ruiz-Irastorza et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants
M. M. Samama et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity
Jochen Graff et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation
G. T. Gerotziafas et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
S Miyakis et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
D Kubitza et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome(WAPS)
G Finazzi et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 -: an oral, direct Factor Xa inhibitor
E Perzborn et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus
G Ruiz-Irastorza et al.
ARCHIVES OF INTERNAL MEDICINE (2004)
A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome
MA Crowther et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Calibrated automated thrombin generation measurement in clotting plasma
HC Hemker et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2003)
Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins
A Tripodi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Epidemiology of the antiphospholipid antibody syndrome
M Petri
JOURNAL OF AUTOIMMUNITY (2000)
分享论文
